Anaptysbio Inc Revenue Growth Rates (ANAB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Anaptysbio Inc   (NASDAQ: ANAB)
 

ANAB's Revenue Growth by Quarter and Year

Anaptysbio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ANAB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 25.56
FY 25.56

ANABs Annual Revenue
Anaptysbio Inc 's Revenue in the fiscal year 2025 $ 234.60 millions
Anaptysbio Inc 's Revenue in the fiscal year 2024 $ 91.28 millions
Anaptysbio Inc 's Revenue in the fiscal year 2023 $ 17.16 millions
Anaptysbio Inc 's Revenue in the fiscal year 2022 $ 10.29 millions
Anaptysbio Inc 's Revenue in the fiscal year 2021 $ 63.18 millions




ANAB Revenue first quarter 2026 Y/Y Growth Comment
Anaptysbio Inc reported decrease in Revenue in the first quarter 2026 by -7.97% to $ 25.56 millions, from the same quarter in 2025.
The decrease in the first quarter 2026 Anaptysbio Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 140.73%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue growth. While Anaptysbio Inc ' s Revenue decline of -7.97% ranks overall at the positon no. 456 in the first quarter 2026.


ANAB Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 151.1 % 378.47 % 32.31 %
3rd Quarter September - 154.23 % 804.22 % 157.36 %
2nd Quarter June - 102.92 % 217.05 % 183.61 %
1st Quarter March -7.97 % 286.77 % 424.09 % 41.24 %
FY   - 157.01 % 431.93 % -

Financial Statements
Anaptysbio Inc 's first quarter 2026 Revenue $ 25.56 millions ANAB's Income Statement
Anaptysbio Inc 's first quarter 2025 Revenue $ 27.77 millions Quarterly ANAB's Income Statement


ANAB Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 41.84 % 43.6 % 171.39 %
3rd Quarter September - 242.86 % 173.66 % -4.05 %
2nd Quarter June - -19.84 % 52.79 % 152.55 %
1st Quarter March -76.39 % -35.58 % -20.31 % -79.88 %
FY (Year on Year)   - 157.01 % 431.93 % -


Back to ANAB Growth rate Comparisons >> Back to ANAB Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #104
Overall #456

Revenue Y/Y Growth Statistics
High Average Low
432.03 % 140.73 % -96.32 %
(Dec 31 2024)   (Sep 30 2022)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #104
Overall #456
Revenue Y/Y Growth Statistics
High Average Low
432.03 % 140.73 % -96.32 %
(Dec 31 2024)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Anaptysbio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
426.53 % 52.34 % -100 %
(Dec 31 2022)  


ANAB's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Anaptysbio Inc disclosed fall in Revenue from the fourth quarter by -76.39% to $ 25.56 millions, from $ 108.25 millions achived in the previous reporting period.

But that's not important problem, as Anaptysbio Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue quarter on quarter growth. While Anaptysbio Inc 's Revenue growth quarter on quarter, overall rank is 2722.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #377
Overall #2722
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #377
Overall #2722
Revenue Q/Q Growth Statistics
High Average Low
426.53 % 52.34 % -100 %
(Dec 31 2022)  


ANAB's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Anaptysbio Inc disclosed fall in Revenue from the fourth quarter by -76.39% to $ 25.56 millions, from $ 108.25 millions achived in the previous reporting period.

But that's not important problem, as Anaptysbio Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue quarter on quarter growth. While Anaptysbio Inc 's Revenue growth quarter on quarter, overall rank is 2722.


Anaptysbio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 232.39 $ 234.60 $ 169.47 $ 123.16 $ 111.87
Y / Y Revenue Growth (TTM) 107.73 % 157.01 % 196.42 % 304.17 % 387.2 %
Year on Year Revenue Growth Overall Ranking # 28 # 14 # 30 # 71 # 28
Seqeuential Revenue Change (TTM) -0.94 % 38.44 % 37.59 % 10.09 % 22.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 456 # 111 # 98 # 300 # 167


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Anaptysbio Inc 's cumulative twelve months Revenue were $ 232 millions, company would post below average annual Revenue growth of 22.56% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Anaptysbio Inc 's Revenue growth from the 108.25% growth in Dec 31 2025.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 14 to 28.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 12
Overall # 28

Revenue TTM Y/Y Growth Statistics
High Average Low
432.03 %
 140.73 %
-96.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 104
S&P 500 # 456
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Anaptysbio Inc 's cumulative twelve months Revenue were $ 232 millions, company would post below average annual Revenue growth of -96.32% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Anaptysbio Inc 's Revenue growth from the 108.25% growth in Dec 31 2025.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 14 to 28.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 12
Overall # 28

Revenue TTM Y/Y Growth Statistics
High Average Low
432.03 %
140.73 %
-96.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 104
S&P 500 # 456




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANAB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Anaptysbio Inc Revenue Growth Rates (ANAB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Anaptysbio Inc (CIK 1370053).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-219515
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Anaptysbio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.